ORG Wealth Partners LLC Purchases 1,227 Shares of Illumina, Inc. (NASDAQ:ILMN)

ORG Wealth Partners LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 68.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,030 shares of the life sciences company’s stock after buying an additional 1,227 shares during the quarter. ORG Wealth Partners LLC’s holdings in Illumina were worth $405,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC boosted its stake in Illumina by 2.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 18,170 shares of the life sciences company’s stock worth $2,369,000 after acquiring an additional 394 shares in the last quarter. Weybosset Research & Management LLC raised its holdings in shares of Illumina by 14.3% during the fourth quarter. Weybosset Research & Management LLC now owns 20,638 shares of the life sciences company’s stock valued at $2,758,000 after purchasing an additional 2,586 shares during the period. Partnership Wealth Management LLC boosted its position in shares of Illumina by 17.0% during the 4th quarter. Partnership Wealth Management LLC now owns 8,095 shares of the life sciences company’s stock worth $1,082,000 after purchasing an additional 1,175 shares in the last quarter. Douglas Lane & Associates LLC grew its stake in shares of Illumina by 1.5% in the 4th quarter. Douglas Lane & Associates LLC now owns 294,787 shares of the life sciences company’s stock valued at $39,392,000 after buying an additional 4,442 shares during the period. Finally, Everence Capital Management Inc. bought a new stake in Illumina in the 4th quarter valued at about $414,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ ILMN traded down $4.22 during mid-day trading on Friday, hitting $135.46. 531,349 shares of the company’s stock traded hands, compared to its average volume of 1,255,647. The company has a market capitalization of $21.48 billion, a P/E ratio of -13.60 and a beta of 1.11. The company’s 50-day moving average is $141.37 and its two-hundred day moving average is $132.08. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 earnings per share. On average, equities analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Piper Sandler dropped their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Barclays increased their price objective on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Finally, TD Cowen upped their price objective on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $165.95.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.